Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
Luis E. Aguirre(Harvard University), Maximilian Stahl(Harvard University), Eric S. Winer(Providence College), Marlise R. Luskin(Dana-Farber Cancer Institute), Sylvain Garciaz(Centre National de la Recherche Scientifique), Martha Wadleigh(Dana-Farber Cancer Institute), Shai Shimony(Twitter (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Rebecca P. Bystrom(Dana-Farber Cancer Institute), Andrius Žučenka(Vilnius University), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Richard M. Stone(Dana-Farber Cancer Institute), Leora Boussi(Beth Israel Deaconess Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Rory M. Shallis(Smilow Cancer Hospital), Yiwen Liu(University of Arizona), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Amer M. Zeidan(Yale University), Kelly Ling(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k